Blog: You, us, everyone

We keep enjoying Thanksgiving and all other regular family meetings – this is perfectly right except that with each run, we put a little more weight on.

But, thanks to the pharmaceutical industry, this is going to change. Eli Lilly won US approval to use the active ingredient in its diabetes drug as a treatment for obesity. Zepbound, as the new weight-loss treatment is called, will cost about $1,100 for a month’s supply. That’s cheaper than Wegovy, a similar drug made by Novo Nordisk, which is about $1,350 for a month’s supply. Yet, for investors, this is a market opportunity exceeding USD 120 billion. Irrespective of the long-term health risks that will be associate with weight-loss drugs, everybody, from airlines, Walmart, to FedEx, not to forget the big Pharma, is rushing into the mater. For how long?